154387-62-9 Usage
Description
(5a,6a,17)-N-(1,1-Dimethylethyl)-6-hydroxy-3-oxo-4-azaandrost-1-ene-17-carboxamide, also known as Finasteride (F342000) (M-4 metabolite), is a synthetic compound derived from the steroidal structure. It is a metabolite of Finasteride, a medication primarily used for treating benign prostatic hyperplasia and androgenetic alopecia. (5a,6a,17)-N-(1,1-Dimethylethyl)-6-hydroxy-3-oxo-4-azaandrost-1-ene-17-carboxamide exhibits structural similarities to the parent drug, which may contribute to its potential applications in various fields.
Uses
Used in Pharmaceutical Applications:
(5a,6a,17)-N-(1,1-Dimethylethyl)-6-hydroxy-3-oxo-4-azaandrost-1-ene-17-carboxamide is used as a metabolite of Finasteride (F342000) for its potential therapeutic effects. As a derivative of Finasteride, it may possess similar pharmacological properties, making it a candidate for further research and development in the pharmaceutical industry. Its application could be in the treatment of conditions related to androgenetic alopecia and benign prostatic hyperplasia, as well as other potential therapeutic areas.
Used in Research and Development:
In the field of research and development, (5a,6a,17)-N-(1,1-Dimethylethyl)-6-hydroxy-3-oxo-4-azaandrost-1-ene-17-carboxamide is used as a valuable compound for studying the structure-activity relationships of steroidal drugs. Its synthesis and evaluation can provide insights into the design and optimization of novel therapeutic agents with improved efficacy and reduced side effects.
Used in Drug Metabolism Studies:
(5a,6a,17)-N-(1,1-Dimethylethyl)-6-hydroxy-3-oxo-4-azaandrost-1-ene-17-carboxamide is used as a model compound in drug metabolism studies. Understanding its metabolic pathways and the enzymes involved can help researchers predict the pharmacokinetic and pharmacodynamic properties of related compounds, ultimately contributing to the development of safer and more effective medications.
Check Digit Verification of cas no
The CAS Registry Mumber 154387-62-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,3,8 and 7 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 154387-62:
(8*1)+(7*5)+(6*4)+(5*3)+(4*8)+(3*7)+(2*6)+(1*2)=149
149 % 10 = 9
So 154387-62-9 is a valid CAS Registry Number.
InChI:InChI=1/C23H36N2O3/c1-21(2,3)25-20(28)16-7-6-14-13-12-17(26)19-23(5,11-9-18(27)24-19)15(13)8-10-22(14,16)4/h9,11,13-17,19,26H,6-8,10,12H2,1-5H3,(H,24,27)(H,25,28)/t13-,14-,15-,16+,17-,19+,22-,23+/m0/s1
154387-62-9Relevant articles and documents
High-resolution mass spectrometric investigation of the phase i and II metabolites of finasteride in pig plasma, urine and bile
Lundahl, Anna,Tevell ?berg, Annica,Bondesson, Ulf,Lennern?s, Hans,Hedeland, Mikael
, p. 498 - 510 (2014)
The metabolite profile of the 5α-reductase type II inhibitor finasteride has been studied in pig plasma, urine and bile using high-resolution mass spectrometry. The porcine biotransformation products were compared to those formed by human liver microsomes and to literature data of recently identified human in vivo metabolites. The objective of this study was to gain further evidence for the validity of using pigs for advanced, invasive drug-drug interaction studies that are not possible to perform in humans.The use of high-resolution mass spectrometry with accurate mass measurements enabled identification of the metabolites by calculation of their elemental compositions as well as their fragmentation patterns.There was an excellent match between the porcine and human metabolic profiles, corroborating the pig as a model of human drug metabolism. The glucuronides of the two recently described human hydroxylated metabolites MX and MY and the carboxylated metabolite M3 were identified as the major biotransformation products of finasteride in pig urine and bile.Furthermore, the CYP enzymes involved in the formation of the hydroxylated metabolites were characterized. Human recombinant CYP3A4 could produce the two major hydroxylated metabolites MX and MY, whereas human recombinant CYP2D6 formed MY only.
